PHMMF Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 19:16):

Stats
Šios dienos apimtis	1 925.00
Vidutinė apimtis	93.00
Rinkos kapitalizacija	555.69M
EPS	$0.280 ( 2023-06-30 )
Kita pelno data	( $0 ) 2024-05-30
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	259.58
ATR14	$0.0790 (0.25%)

Tūris Koreliacija

Ilgas: -0.16 (neutral)

Trumpas: 0.33 (neutral)

Signal:(33.971) Neutral

Pharma Mar, S.A. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Pharma Mar, S.A. Koreliacija - Valiuta/Žaliavos

0.56
( weak )

0.32
( neutral )

0.53
( weak )

0.54
( weak )

0.19
( neutral )

-0.46
( neutral )

Pharma Mar, S.A. Finansinės ataskaitos

Annual	2023
Pajamos:	$158.15M
Bruto pelnas:	$144.86M (91.60 %)
EPS:	$0.0635

FY	2023
Pajamos:	$158.15M
Bruto pelnas:	$144.86M (91.60 %)
EPS:	$0.0635

FY	2022
Pajamos:	$196.34M
Bruto pelnas:	$182.70M (93.05 %)
EPS:	$2.73

Financial Reports:

No articles found.

Pharma Mar, S.A. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Pharma Mar, S.A.

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.